Am­gen, As­traZeneca speed to­ward fil­ing next-gen an­ti­body for asth­ma af­ter un­cork­ing full late-stage da­ta

On the hunt for a nov­el com­peti­tor to Sanofi and Re­gen­eron’s Dupix­ent in se­vere asth­ma, Am­gen and As­traZeneca post­ed “ex­cit­ing” re­sults from their next-gen an­ti­body late last year. Now, the part­ners are show­ing their hands, and the re­sults look good enough for ap­proval.

Am­gen and As­traZeneca’s teze­pelum­ab plus stan­dard of care cut the rate of se­vere asth­ma at­tacks by 56% at the one-year mark com­pared with SOC alone, ac­cord­ing to full da­ta from the Phase III NAV­I­GA­TOR study pre­sent­ed Fri­day at the vir­tu­al Amer­i­can Acad­e­my of Al­ler­gy, Asth­ma & Im­munol­o­gy meet­ing. And those sig­nif­i­cant re­sults were con­sis­tent re­gard­less of pa­tients’ base­line eosinophil counts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER